Loading data for LBRX — first visit, this takes a few seconds.

알림

LB Pharmaceuticals Inc (LBRX)

NasdaqGM: LBRX · 실시간 가격 · USD

48.77

+2.54 (5.49%)

종가 기준: Aug 19, 2026, 11:12 AM

5.49% (1D)

매수호가	n/a
시가총액	1.57B
매출 (ttm)	n/a
순이익 (ttm)	-85.69M
베타	n/a
EPS (ttm)	-5.38
P/E (ttm)	n/a
선행 P/E	-9.86
P/B (ttm)	4.21
P/S (ttm)	n/a
Earnings Date	Nov 12, 2026

매도호가	n/a
거래량	538,856
평균 거래량 (20일)	322,916
시가	45.69
전일 종가	46.23
일중 범위	45.69 - 48.93
52주 범위	13.36 - 49.14
애널리스트	n/a
목표주가	n/a
배당	n/a
배당락일	n/a

LBRX 소개

LB Pharmaceuticals Inc, a clinical-stage biopharmaceutical company, develops therapies for the treatment of schizophrenia, bipolar depression, and other neuropsychiatric diseases. Its lead product is LB-102, a small molecule oral product, which is in Phase 3 clinical trial for the treatment of acute schizophrenia; completed Phase 2 clinical trial for the treatment of bipolar I depression; adjunctive treatment of MDD; and in pre-clinical stage for...

[더 보기]

산업 Biotechnology

섹터 Healthcare

IPO 일자 Sep 11, 2025

직원 수 49

상장 거래소 NasdaqGM

티커 LBRX

웹사이트 https://lbpharma.us

전체 기업 정보

재무 실적

2025년 LB Pharmaceuticals Inc의 매출은 0로, 전년 0 대비 undefined% 증가했습니다. 순이익은 -25.2M로, -60.06% 감소했습니다.

재무제표

어닝 서프라이즈

LB Pharmaceuticals Inc가 Aug 11, 2026에 분기 실적을 발표했습니다:

매출 $0 예상치 하회 $0, 및 NaN% 전년 대비 성장.

EPS -1.71 예상치 하회 -0.91, 및 -Infinity% 전년 대비 감소.

다음 실적 발표

LB Pharmaceuticals Inc의 실적 발표 예정일은 Nov 12, 2026, 장 시작 전입니다.
애널리스트 예상 매출은 ... 업그레이드

뉴스

4주 전 · The Fly

Shopify downgraded, Five Below upgraded: Wall Street's top analyst calls

1개월 전 · Insider Monkey

LB Pharmaceuticals Inc. (LBRX) Maintains Buy Rating as Analyst Highlights LB-102 Potential

We recently compiled a list of the 8 Best Up and Coming Pharmaceutical Stocks to Buy Now. LB Pharmaceuticals Inc. (NASDAQ:LBRX) is one of the best up and coming stocks on our list. TheFly reported on ...

2개월 전 · Motley Fool

Nan Fung Group Sells $4.3 Million in Oculis Shares As Lead Drug Stumbles

Oculis advances late-stage topical therapies for diabetic and neuro-ophthalmic eye diseases in the clinical-stage biotech sector.

2개월 전 · Zacks

All You Need to Know About LB Pharmaceuticals Inc (LBRX) Rating Upgrade to Buy

LB Pharmaceuticals Inc (LBRX) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

3개월 전 · Simply Wall St.

LB Pharmaceuticals (NASDAQ:LBRX) Is In A Good Position To Deliver On Growth Plans

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...

2 페이지 중 1

LB Pharmaceuticals Inc (LBRX)